LinkOPH

Using a one-time injection to replace antibiotic and anti-inflammation eye drop therapy associated with cataract surgery has the potential for saving government payers and patients billions of dollars over time, according to an economic impact study cited by Imprimis Pharmaceuticals in a press release.The study, promulgated by Cataract Surgeons for Improved Eyecare and funded in part by Imprimis Pharmaceuticals, found that over 10 years, potential cost savings for patients, Medicare and Medicaid was “a most likely savings estimate of $8.7 billion.”

Read more →

MENLO PARK, Calif. – Transcend Medical Inc. and Glaukos Corp. reached an agreement to settle a patent lawsuit in the U.S. District Court in Delaware, Transcend Medical announced today in a press release.Glaukos had filed suit against Transcend Medical concerning the patent for Transcend Medical’s CyPass micro-stent.

Read more →

A customizable compounded formulation of pyrimethamine and leucovorin has been made available for prescription at the approximate price of $1 per pill, according to a press release from Imprimis Pharmaceuticals.The treatment is a low-cost alternative to Daraprim (pyrimethamine, Turing Pharmaceuticals), the price of which was recently increased to $750 per tablet according to the Infectious Diseases Society of America and the HIV Medicine Association. Imprimis’ finished compounded drug formulations are not approved by the FDA for recommended use, and are only to be prescribed to individually identified patients consistent with federal and state compounded drug formulation laws.

Read more →

Thea Acquisition Corp., an indirect wholly owned subsidiary of Sun Pharma, has completed the cash tender offer for all outstanding shares of InSite Vision’s common stock, Sun Pharma announced in a press release. InSite’s outstanding shares of common stock expired on Oct. 27.

Read more →

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE:GKOS) announced today that it has entered into a settlement agreement with Transcend Medical, Inc. to resolve all existing patent litigation between the two companies. Under the settlement agreement, Glaukos grants Transcend a covenant not to sue Transcend for patent infringement in connection with Transcend’s CyPass Micro-Stent devices, appliers and delivery systems. In exchange, Transcend grants Glaukos a covenant not to challen

Read more →